Soaring Demand Set to Propel Candidiasis Therapeutics Market to $3.83 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Candidiasis Therapeutics Market Through 2025?
In recent times, the market size of candidiasis therapeutics has witnessed stable expansion. The market, which is set to grow from $3.19 billion in 2024 to $3.3 billion in 2025, is projected to follow a compound annual growth rate (CAGR) of 3.4%. Factors such as elevated occurrence of candidiasis, use of antibiotics and resistance, hospital-gained infections, shift in fungal resistance patterns, and the institution of awareness and education programs account for the growth during the historic period.

What's the Projected Size of the Global Candidiasis Therapeutics Market by 2029?
In the coming years, the market for candidiasis therapeutics is projected to experience consistent growth. With a compound annual growth rate (CAGR) of 3.8%, it is predicted to reach $3.83 billion by 2029. The anticipated expansion during this period can be credited to factors such as approaches to precision medicine, international antifungal stewardship programs, a rising incidence of candida auris, and global endeavors to counter antifungal resistance. Key trends projected for this timeframe include progress in drug delivery technologies, utilisation of telemedicine and remote patient observation, focus on patient-oriented care, combination treatment strategies, and cooperative research initiatives.

View the full report here:
https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report

Top Growth Drivers in the Candidiasis Therapeutics Industry: What's Accelerating the Market?
The high incidence of fungal infections is predicted to bolster the expansion of the candidiasis therapeutics market. These infections, which are the result of various fungi, can affect human skin, mucous membranes, and internal organs. The prevalent rate of individuals with compromised immune systems and fungal infections enhances vulnerability to candidiasis, thus generating opportunities for drug developers to create and distribute specialized and highly effective antifungal remedies that combat the root cause of fungal pathogens, alleviate symptoms, prevent complications, and support patients' recovery process. This also aids in limiting the spread of Candida infections within healthcare facilities, enabling better patient outcomes. The University of Minnesota revealed in January 2024 that fungal infections result in over 3.75 million deaths per annum, with around 2.55 million of these fatalities directly linked to fungal diseases. Hence, the escalating incidence of fungal infections is predicted to stimulate the growth of the candidiasis therapeutics market. The surge in clinical trials is set to drive the expansion of the candidiasis therapeutics market. These trials are research studies designed to validate the safety and effectualness of newly developed medical treatments, interventions, drugs, or devices on humans. They are integral to the advancement of candidiasis therapeutics as they offer a systematic, rigorous process to test the safety and effectualness of potential treatments. As per ClinicalTrials.gov, which is a part of the National Institutes of Health, a US government agency accountable for conducting and sponsoring medical research, roughly 437,533 clinical trials were recorded in May 2023, compared to 399,499 recorded studies in 2022 in all 50 states of the United States and across 221 countries. Thus, the surge in clinical trials propels the growth of the candidiasis therapeutics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13182&type=smp

What Trends Will Shape the Candidiasis Therapeutics Market Through 2029 and Beyond?
In the candidiasis therapeutics market, key companies are focusing on the creation of novel medications like BREXAFEMME (ibrexafungerp tablets), with the aim to lessen the occurrences of recurrent vulvovaginal candidiasis (RVVC) in women. An oral, non-azole drug, BREXAFEMME is designed to treat vulvovaginal candidiasis (VVC) and diminish instances of recurrence, often referred to as chronic yeast infections. For example, Scynexis Inc., a pharmaceutical firm based in the US, obtained approval from the US Food and Drug Administration (FDA) in December 2022 for the use of BREXAFEMME in treating VVC and reducing RVVC, or chronic yeast infections. The mechanism of BREXAFEMME is to inhibit the proliferation of Candida albicans, the causative agent of VVC. It's a safe and reliable medication option for treating VVC and can only be acquired by prescription. The suggested dosage is a single 150-mg capsule taken orally once a day for a day.

What Are the Main Segments in the Candidiasis Therapeutics Market?
The candidiasis therapeutics market covered in this report is segmented -

1) By Treatment Type: Medication, Surgery, Other Treatments
2) By Anatomy Type: Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis
3) By Mode Of Administration: Injectable, Oral, Other Mode Of Administrations
4) By Patient Population: Adults, Pediatrics
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Medication: Antifungal Drugs, Topical Treatments, Systemic Treatments
2) By Surgery: Surgical Debridement, Organ Removal
3) By Other Treatments: Probiotics, Home Remedies, Lifestyle Modifications

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13182&type=smp

Which Top Companies are Driving Growth in the Candidiasis Therapeutics Market?
Major companies operating in the candidiasis therapeutics market report are Pfizer Inc., Biocon Limited, Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc., GSK plc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Cipla Inc., Bruker Corporation, Lupin Limited, Galapagos NV, Basilea Pharmaceutica Ltd., WOCKHARDT Limited, Pacgen Life Science Corporation, Cidara Therapeutics Inc., Ablynx NV, Amplyx Pharmaceuticals Inc., NovaDigm Therapeutics Inc., SCYNEXIS Inc., Medivir AB, Mycovia Pharmaceuticals Inc., NovaBiotics Inc., Matinas BioPharma Holdings Inc.

Which Regions Will Dominate the Candidiasis Therapeutics Market Through 2029?
North America was the largest region in the candidiasis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candidiasis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13182

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.